Home
/

GH Deficiency

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Key takeaway:

Blood testing for growth hormone deficiency focuses on IGF-1 (insulin-like growth factor 1), a stable liver-derived marker read against age- and sex-specific ranges, because GH itself pulses throughout the day. Low IGF-1 is associated with reduced protein synthesis, increased visceral fat, lower lean mass, fatigue, and bone loss, helping clarify risks like osteoporosis and cardiovascular changes.

Read more →
Table of contents

GH Deficiency and the Markers That Hint at It

GH deficiency biomarkers are blood signals that show how well the body’s growth-hormone system is working. Growth hormone (GH, somatotropin) is released from the anterior pituitary (somatotrophs) in short bursts and vanishes quickly, so a single GH level rarely captures the true picture. Instead, testing focuses on the steadier messengers made in response to GH—mainly insulin-like growth factor 1 (IGF‑1) and its carrier protein IGF‑binding protein‑3 (IGFBP‑3), produced largely by the liver (hepatocytes) with support from the acid‑labile subunit (ALS). These downstream markers integrate GH activity over time, acting as a durable readout of the somatotropic axis. Measuring them helps determine whether growth signaling to bones, muscles, and metabolism is adequate, establishes an objective baseline, and tracks how the system responds over time to treatment. Together, they translate the fleeting GH pulse into a stable biological story—how effectively the pituitary’s signal is being generated, transported, and received across the body.

Why IGF-1 Tells a Steadier Story Than GH

GH deficiency testing focuses on the GH–IGF‑1 axis. Because GH is secreted in pulses, steady blood markers—insulin‑like growth factor‑1 (IGF‑1), and in children IGFBP‑3—best reflect overall GH activity across systems that govern growth, body composition, bone turnover, metabolism, and cardiovascular health.IGF‑1 is read against age‑ and sex‑specific ranges or a Z‑score. In adults, healthy values cluster around the mid‑range for age; values near or below the lower limit suggest impaired GH action, while very high values point to GH excess, not deficiency.When IGF‑1 is low for age, it usually reflects reduced GH secretion or bioactivity. Physiology shifts toward less protein building and fat breakdown, raising visceral fat, lowering lean mass, and slowing bone remodeling. Adults feel fatigue, reduced strength and stamina, larger waistlines, worse lipids, and bone loss. Children show slow linear growth and delayed skeletal maturation. Pregnancy relies on placental GH and rising IGF‑1, so results must be interpreted in that physiologic context.An elevated IGF‑1 typically rules out GH deficiency and raises concern for GH excess, which can produce soft‑tissue swelling, headaches, sleep apnea, insulin resistance, and cardiometabolic risk.Big picture, IGF‑1 bridges nutrition, thyroid and liver function, and pituitary output. Read with GH stimulation tests and clinical features, it links the GH axis to muscle, bone, fat, and heart health, clarifying risks like osteoporosis, visceral adiposity, and cardiovascular disease.

The Honest Limits of GH Screening Blood Work

Growth hormone (GH) deficiency blood testing provides insight into how well your body supports growth, tissue repair, metabolism, and overall vitality. GH is a key hormone that influences energy levels, muscle and bone strength, cardiovascular health, cognitive function, and immune resilience. At Superpower, we assess GH status by measuring a specific biomarker: IGF-1.IGF-1, or insulin-like growth factor 1, is a protein produced mainly in the liver in response to GH stimulation. Because GH itself is released in pulses and can be difficult to measure directly, IGF-1 serves as a stable indicator of average GH activity over time. Low IGF-1 levels can suggest GH deficiency, while normal or high levels generally indicate adequate GH function.A healthy IGF-1 level reflects the body’s ability to maintain stable growth, repair tissues, and regulate metabolism. When IGF-1 is within the expected range for age and sex, it supports the body’s capacity for cellular renewal, muscle maintenance, and metabolic balance. In the context of GH deficiency, low IGF-1 may signal reduced anabolic (building) processes and can be associated with symptoms like fatigue, decreased muscle mass, and changes in body composition.It’s important to note that IGF-1 levels naturally decline with age and can be influenced by factors such as acute illness, chronic disease, pregnancy, nutritional status, and certain medications. Laboratory methods and reference ranges may also vary, so results are best interpreted in context.

FAQs

It evaluates how well your growth hormone system is working by measuring a stable downstream signal in your blood. Superpower tests your blood for IGF-1 (insulin-like growth factor 1), which reflects average GH action from the liver over days, not minutes. Random GH itself pulses and is unreliable. Low age- and sex-adjusted IGF-1 suggests reduced GH axis activity; normal values make severe deficiency less likely; very high values suggest GH excess. When results are unclear, dynamic GH stimulation tests may be needed to confirm physiology.

GH signaling influences body composition, bone mineral density, lipid metabolism, cardiovascular risk, and vitality. Measuring IGF-1 gives a steady readout of the somatotropic axis, helping explain slow growth (in youth), low bone density, adverse fat distribution, or low energy in adults. Superpower tests your blood for IGF-1 to screen for clinically meaningful GH deficiency or excess and to provide context for symptoms that may reflect hypothalamic–pituitary–liver pathway dysfunction.

Yes. With Superpower, our team can organize a licensed professional to draw your blood at home for IGF-1 testing. The sample is processed by a certified laboratory, and results are interpreted in the context of your age and sex. This keeps the process convenient while preserving analytical quality and clinical accuracy for assessing your growth hormone–IGF axis.

For screening, a single IGF-1 is often enough. Retest if your clinical picture changes, after significant health shifts (illness, weight change, new medications), or when monitoring dose adjustments if you are on GH therapy. During GH dose titration, IGF-1 is typically checked more frequently, then periodically to ensure levels remain in the target age-adjusted range. Otherwise, routine repeat testing is not needed without a new question to answer.

Age and sex strongly shape the reference range. Puberty and pregnancy raise IGF-1; aging lowers it. Liver disease, kidney disease, hypothyroidism, uncontrolled diabetes, malnutrition, and systemic inflammation can lower IGF-1 independent of GH secretion. Oral estrogens, glucocorticoids, and androgens alter readings. Obesity reduces GH secretion and may blunt IGF-1. Acute illness, recent strenuous exercise, and assay differences also shift values. These factors are considered when interpreting your result.

No special prep is required. You do not need to fast, and time of day is not critical because IGF-1 is stable. Very high-dose biotin supplements can interfere with some immunoassays; avoiding them for 24–72 hours helps prevent false results. If you use oral estrogen, are acutely ill, or recently had major changes in diet or weight, results may shift; this context is used in interpretation.

References

  1. Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011). Evaluation and treatment of adult growth hormone deficiency: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 96(6), 1587-1609. https://doi.org/10.1210/jc.2011-0179
  2. Yuen, K. C. J., Biller, B. M. K., Radovick, S., Carmichael, J. D., Jasim, S., Pantalone, K. M., & Hoffman, A. R. (2019). American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocrine Practice, 25(11), 1191-1232. https://doi.org/10.4158/GL-2019-0405
  3. Clemmons, D. R. (2011). Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clinical Chemistry, 57(4), 555-559. https://doi.org/10.1373/clinchem.2010.150631
  4. National Institute of Diabetes and Digestive and Kidney Diseases. (2021). Acromegaly. https://www.niddk.nih.gov/health-information/endocrine-diseases/acromegaly
  5. MedlinePlus. (n.d.). Growth hormone deficiency. https://medlineplus.gov/ency/article/001176.htm

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey